Medtronic
710 Medtronic Parkway, NE
Minneapolis
Minnesota
55432-5604
United States
Website: http://www.medtronic.com/
2289 articles with Medtronic
-
EuroPCR: Medtronic renal denervation system shows better blood pressure control with significantly more time in target range
5/17/2022
Medtronic plc announced data showing the benefits of the Symplicity Blood Pressure Procedure with the Symplicity Spyral™ Renal Denervation system on achieving target blood pressure level ranges.
-
Medtronic completes acquisition of Intersect ENT
5/13/2022
Medtronic plc announced that it has completed the acquisition of Intersect ENT, expanding the company's comprehensive ear, nose, and throat portfolio with innovative products used in sinus procedures to improve post-operative outcomes and to treat nasal polyps.
-
Medtronic receives FDA approval for latest generation drug-eluting coronary stent system
5/13/2022
Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced it received U.S. Food and Drug Administration (FDA) approval for the Onyx Frontier™ drug-eluting stent (DES).
-
Biopharma and life sciences organizations from across the globe provide updates on their businesses and pipelines.
-
Medtronic and GE Healthcare announce a collaboration to meet growing need for outpatient care
4/28/2022
Providing excellent care inside and outside of the traditional hospital is the new normal for patients, clinicians, and payers seeking more choices without compromising excellent outcomes.
-
GE Healthcare and Medtronic Announce a Collaboration to Meet Growing Need for Outpatient Care
4/28/2022
Providing excellent care inside and outside of the traditional hospital is the new normal for patients, clinicians, and payers seeking more choices without compromising excellent outcomes.
-
Medtronic names new chief scientific, medical, and regulatory officer
4/25/2022
Medtronic plc announced that Laura Mauri, M.D., M.S.c. has been appointed Medtronic Chief Scientific, Medical and Regulatory Officer.
-
ACC.22: Medtronic renal denervation system demonstrates significant blood pressure reduction through three years
4/4/2022
Medtronic plc which were presented at the American College of Cardiology's 71st Annual Scientific Session late-breaking featured clinical research sessions.
-
Medtronic announces first patient implants of investigational implantable tibial neuromodulation therapy for bladder incontinence
3/24/2022
Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced the first patient implants in the TITAN 2 pivotal study that will evaluate the safety and efficacy of Medtronic's investigational implantable tibial neuromodulation (TNM) device in people with overactive bladder (OAB).
-
Medtronic appoints new Operating Unit Presidents
3/17/2022
Medtronic plc, a global leader in healthcare technology, announced leadership transitions for three of its Operating Units – Diabetes, Surgical Robotics, and Cardiac Rhythm Management – bringing in critical skills and capabilities and creating opportunities for internal talent.
-
First U.S. trial using GI Genius™ intelligent endoscopy module shows 50% reduction in missed colorectal polyps with artificial intelligence (AI) technology versus standard colonoscopy
3/16/2022
Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced final findings from a randomized, international, multi-center study that confirmed the effectiveness of the GI Genius™ intelligent endoscopy module, which uses AI as an aid in detecting colorectal polyps during colonoscopy, potentially helping to prevent colorectal cancer (CRC).
-
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
-
Medtronic announces contract with Vizient for Touch Surgery™ Enterprise
3/9/2022
Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced it has entered into a contract with Vizient, a leading healthcare performance improvement company in the U.S., to add Touch Surgery™ Enterprise to Vizient's offerings, which serve more than half the nation's healthcare providers.
-
Medtronic announces cash dividend for fourth quarter of fiscal year 2022
3/4/2022
The board of directors of Medtronic plc (NYSE:MDT) on Thursday, March 3, 2022 , approved the fiscal year 2022 fourth quarter cash dividend of $0.63 per ordinary share, representing an 8.6 percent increase over the prior year.
-
Medtronic announces launch of NuVent™ Eustachian tube dilation balloon
2/28/2022
Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced the launch of the NuVent™ Eustachian tube dilation balloon, which has been cleared by the U.S. Food and Drug Administration (FDA) for the treatment of chronic, obstructive Eustachian Tube Dysfunction.
-
Medtronic reports third quarter fiscal 2022 financial results
2/22/2022
Medtronic plc (NYSE: MDT) today announced financial results for its third quarter of fiscal year 2022, which ended January 28, 2022 .
-
Medtronic receives FDA approval for InterStim X™ system, the next generation of the most personalized sacral nerve stimulation therapy for bladder and bowel control
2/22/2022
Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced it received approval from the U.S. Food and Drug Administration (FDA) for InterStim X™ ― the next generation of the InterStim™ portfolio's recharge-free device – and it is available immediately.
-
Medtronic to provide underserved communities with artificial intelligence (AI)-assisted colonoscopy technology through Health Equity Assistance Program for colon cancer screening
2/22/2022
Medtronic plc (NYSE: MDT), a global leader in healthcare technology, and the American Society for Gastrointestinal Endoscopy (ASGE) today announced they are working to provide colorectal cancer screening technologies in low income and underserved communities across the United States through the Medtronic Health Equity Assistance Program for colon cancer screening, with support from Amazon Web Services (AWS).
-
Medtronic receives FDA expanded approval for cardiac cryoablation catheters for pediatric treatment of a common heart rhythm condition
2/18/2022
Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced that the Freezor™ and Freezor™ Xtra Cardiac Cryoablation Catheters are approved by the U.S. Food and Drug Administration (FDA) and are the only ablation catheters approved to treat the growing prevalence of pediatric Atrioventricular Nodal Reentrant Tachycardia (AVNRT).
-
Medtronic to announce financial results for its third quarter of fiscal year 2022
2/8/2022
Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced that it will report financial results for its third quarter of fiscal year 2022 on Tuesday, February 22, 2022.